Press Release
Water Tower Research Highlights Ainos' Transition to Technology Company Following GICS Reclassification
New GICS code increases visibility among technology investors as Ainos builds commercial momentum around its AI-powered digital olfaction platform Expanded partnerships and IP portfolio to strengthen Ainos' SmellTech-as-a-Service model and competitive edge Read More
Press Release
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill
Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscopic improvement and 30.2% achieving clinical remission at the highest dose at Week 12 in the Phase 2b ANTHEM-UC study These data support the promise of a first-in-class targeted oral peptide that selectively blocks the IL-23 receptor as a potential new option for people with moderately to severely active ulcerative colitis Registrational Phase 3 study in ulcerative colitis and Phase 2b/3 study in Crohn's disease anticipated to begin patient enrollment in Q4 2025 Read More
Press Release
PlayMetrics Announces Sale of Professional Sports Video Analysis Platform Steva to Cardinal Sports Capital
The transaction underscores PlayMetrics' commitment to focus exclusively on its core mission: delivering a unified platform that transforms how youth sports organizations operate. Read More
Press Release
Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance
Findings show that Telomir-1 restores the body's natural tumor suppressor defenses by reversing abnormal DNA methylation of MASPIN and RASSF1A - genes that help block invasion, limit metastasis, and improve chemotherapy responsiveness in aggressive prostate cancer models. Read More
Press Release
Resolution Investors Launches Flagship Core Global Equity Strategy, Investing in Quality Public Companies Poised to Benefit From the Climate Transition
Upends Traditional Public Equities Approaches to Climate Investment, Aligning Core, Quality and Climate; Veteran Management Team with More than 100 Years Experience Read More
Press Release
HotelRunner and Visa Partner Globally to Power Embedded and Autonomous Finance in Travel
Uniting the strength of Visa's trusted infrastructure with HotelRunner's deep presence in hospitality, this strategic preferred partnership sets the foundation for a new era of embedded finance in travel. By bringing Visa's products directly into HotelRunner's platform, this collaboration will enable seamless, secure, and scalable cross-border payments and settlements for thousands of travel businesses worldwide. Read More
Press Release
Ultimate Guide to Removing Bad Spells Review 2025: 7-Day Energy Cleanse, Price, Refund Policy and Legitimacy Explained
Discover How This 33-Chapter Digital Program Promises to Clear Negative Energy, Restore Balance and Deliver Real Results - See Why Thousands are Talking About Its 7-Day Energy Reset in 2025 Read More
Press Release
ClearPoint Neuro Announces Expanded International Clearances for Key Therapy Delivery Product; Now Totaling 34 Countries Worldwide
The clearly established history across global regulatory bodies is expected to de-risk BioPharma partners' pathways towards achieving global scale and standardization. Read More
Press Release
Proven ROI Launches Game Changing HubSpot and Encompass API for the Mortgage Industry
A first of its kind API that connects marketing, sales, and loan origination data, empowering mortgage companies to automate processes, close loans faster, and scale smarter at only $1,199 per month with no upfront fees. Read More
Press Release
DEA Marijuana Cruelty Disguised as Process: Will President Trump Stop Delay on Cannabis Medicine For Huntington's and MS Patients
For seven years, a critical application to grow cannabis for FDA approved medicine has languished at the Drug Enforcement Administration (DEA), sparking allegations that the agency is in "blatant violation of federal law" and blocking potential treatments for thousands of patients battling Huntington's Disease (HD) and Multiple Sclerosis (MS). Read More
Press Release
